ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 6

Pregnancy  Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years  Long-Term Observation 

Dana Tegzova1, Katerina Andelova2, Iva Kucerova2, Vera Vlasakova3, Stejskal Jan4, Putova Ivana5, Marta Olejarova6 and Ctibor Dostál7, 1Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, 2Institute of Mother and Child Care, Prague, Prague, Czech Republic, 3Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, 41st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, 5Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, 6Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid antibodies, antiphospholipid syndrome, pregnancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017, to describe the type and severity of it and to explore their relationship with disease-related characteristics. To find specific histological changes in maternal tissue in a subgroup of patients.

Methods: During more than 25 years of systematic observation 80 pregnant women with APS were observed and examined. Secondary APS was in our cohort common with systemic lupus erythematosus (SLE). Patients were evaluated every 3 months by a rheumatologist and gynaecologist. Basic demographic data were assessed, as well as the duration and type of therapy, autoantibodies, organ involvement and its activity, the number and type of disease flares, thrombosis, the number of abortions and premature labours, new-born weight and presence of complications such as gestational diabetes, hypertension and preeclampsia. In a subgroup of 13 patients (5 with primary APS, 7 with sec.APS/SLE a macroscopic and histological examination of maternal tissue was performed in comparison with a healthy control group.

Results: The group comprised 65 pregnant women with APS, out of which 57% had secondary APS/SLE and 33% primary APS. In the group of primary APS 90% pts were treated with low molecular heparin and/or salicylates. In pts. with sec.APS/SLE 90 % of patients were treated with oral corticosteroids, 8% with cyclosporine A and 16% with azathioprine and 95% with low molecular weight heparin and/or salicylates. 7% of pregnancies were terminated in the first trimester due to missed abortion. 6% of abortions in patients with sec. APS/SLE in second trimester were observed. 57 APS patients delivered 58 newborns, 16% of them before the 37th week of pregnancy and 7% before the 34th week. Out of this group 75% patients delivered prematurely due to hypertension or preeclampsia, 10% due to growth retardation of fetus. Newborn weight was 3020g on average. AV heart block of 3rd degree was observed in 1 newborn with sec.APS/SLE. No congenital malformations were observed in our group. In the group sec.APS/SLE higher number of gestational diabetes was found: 38% of patients, all of which were treated with corticosteroids. Hypertension was found in 33% patients, preeclampsia in 12 % and 60% of patients with preeclampsia had a history of lupus nephritis. Higher score of maternal infarcts and decidual pathological changes with deposits of immunocomplexes were found in microscopic examination in patients with APS in comparison with healthy controles. Rate of weight placenta/fetus was lower. Signs of accelerate aging, nodules and inflammatory infiltration was found in light microscopy and higher score of deposits of immunecomplexes were found.

Conclusion: In spite of the fact that women with APS have a high risk during the course of pregnancy, the results of our long terms study showed a good outcome of pregnancy. Higher rate of complications was found in the group with sec. APS with SLE.

Supported by Research Project Ministry of Health of Czech Republic NO: 000 000 23728


Disclosure: D. Tegzova, None; K. Andelova, None; I. Kucerova, None; V. Vlasakova, None; S. Jan, None; P. Ivana, None; M. Olejarova, None; C. Dostál, None.

To cite this abstract in AMA style:

Tegzova D, Andelova K, Kucerova I, Vlasakova V, Jan S, Ivana P, Olejarova M, Dostál C. Pregnancy  Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years  Long-Term Observation  [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pregnancy-outcomes-in-a-cohort-of-women-with-antiphospholipid-syndrome-25-years-long-term-observation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-a-cohort-of-women-with-antiphospholipid-syndrome-25-years-long-term-observation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology